Posted by Michael Wonder on 22 Aug 2022
Gilead announces first global regulatory approval of Sunlenca (lenacapavir), the only twice yearly HIV treatment option
22 August 2022 - European Commission grants marketing authorisation for Sunlenca, helping to address a critical unmet clinical need for people with multi-drug-resistant HIV who have very limited treatment choices.
Gilead Sciences today announced that the European Commission has granted Marketing Authorization for Sunlenca (lenacapavir) injection and tablets for the treatment of HIV infection, in combination with other anti-retroviral(s), in adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.
